My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Gilead Sciences (NQ:GILD)

122.04 +0.82 (+0.68%)

Streaming Delayed Price Updated: 12:00 PM EST, Dec 8, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2 3 4 5 6 7 8 9

...

68 69 Next >

What Does the Market Think About Gilead Sciences Inc? ↗

Today 8:00 EST

Via Benzinga

Yescarta® Delivers Consistent Safety, Efficacy, and Quality of Life Benefits Across Broad Range of Relapsed/Refractory Large B-cell Lymphoma Patients in New Analysis at ASH 2025

December 07, 2025

From Gilead Sciences, Inc.

Via Business Wire

Kite’s Next-Generation Bicistronic CAR T-Cell Therapies Show Encouraging Phase 1 Results in Relapsed/Refractory B-Cell Lymphoma in New Data at ASH 2025

December 06, 2025

From Gilead Sciences, Inc.

Via Business Wire

Kite Announces New Data for Pivotal iMMagine-1 Study at ASH 2025, Highlighting Anito-cel’s Opportunity in Relapsed or Refractory Multiple Myeloma

December 06, 2025

From Gilead Sciences, Inc.

Via Business Wire

Merck Says Its Two-Drug Regimen For HIV Treatment Proven Non-Inferior To Gilead’s Biktarvy In Study ↗

November 19, 2025

Via Stocktwits

3 Unpopular Stocks We Think Twice About

December 03, 2025

Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can...

Via StockStory

Scholar Rock Stock Is Still Down 40% From 2021 Highs — And One Investor Just Walked Away ↗

December 03, 2025

This investor just walked away as Scholar Rock heads into a pivotal 2026—here’s what that means for long-term shareholders.

Via The Motley Fool

Topics Regulatory Compliance

5 Healthcare Names to Watch as Sector Rotation Is in Full Swing ↗

December 01, 2025

Via MarketBeat

Here's How Much $1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today ↗

November 28, 2025

Via Benzinga

Top S&P500 movers in Friday's session ↗

November 28, 2025

Let's delve into the developments on the US markets one hour before the close of the markets on Friday. Below, you'll find the top gainers and losers within the S&P500 index during today's session.

Via Chartmill

These S&P500 stocks are moving in today's session ↗

November 28, 2025

Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Friday.

Via Chartmill

Gapping S&P500 stocks in Friday's session ↗

November 28, 2025

Curious about the S&P500 stocks that are gapping on Friday? Explore the gap up and gap down stocks in the S&P500 index during today's session.

Via Chartmill

Kymera (KYMR) Q3 2025 Earnings Call Transcript ↗

November 27, 2025

Kymera (KYMR) Q3 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Gilead Sciences Inc (NASDAQ:GILD) Demonstrates Strong Dividend Reliability and Profitability ↗

November 25, 2025

Gilead Sciences (GILD) is a reliable dividend stock with a 2.53% yield, 10-year payment history, and a low payout ratio. Strong profitability and a debt-free balance sheet support its sustainable...

Via Chartmill

Gilead Foundation Commits Over $3 Million to Address Food Insecurity

November 24, 2025

From Gilead Sciences, Inc.

Via Business Wire

$1000 Invested In Gilead Sciences 5 Years Ago Would Be Worth This Much Today ↗

November 20, 2025

Via Benzinga

Gilead Sciences Inc Chart Analysis ↗

November 19, 2025

Technical analysis on the stock chart for GILD.

Via Talk Markets

Merck's Investigational Two-Drug Regime Matches Gilead's Three-Drug Tablet For HIV Treatment ↗

November 19, 2025

Merck's HIV pill met key efficacy and safety goals in Phase 3 trials, matching Biktarvy as the FDA reviews its application with a 2026 decision date.

Via Benzinga

Wall Street Braces for Impact as Delayed Jobs Report Emerges from Data Blackout

November 19, 2025

New York, NY – November 19, 2025 – Wall Street is on high alert as the highly anticipated September 2025 jobs report, a critical barometer of the nation's economic health, is finally set to be released...

Via MarketMinute

Topics Artificial Intelligence Bonds Economy

Uncover the latest developments among S&P500 stocks in today's session. ↗

November 18, 2025

Curious about the top performers within the S&P500 index in the middle of the day on Tuesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.

Via Chartmill

Gilead Joins Partners for Delivery of First Shipments of Breakthrough Twice-yearly Lenacapavir for HIV Prevention to Sub-Saharan Africa

November 18, 2025

From Gilead Sciences, Inc.

Via Business Wire

Gilead Sciences's Options: A Look at What the Big Money is Thinking ↗

November 17, 2025

Via Benzinga

Healthcare Sector Navigates Mixed Market Close: A Beacon of Stability Amidst Uncertainty

November 14, 2025

As the broader market concluded with a mixed performance on November 14, 2025, the S&P 500 Healthcare sector once again underscored its often-defensive nature, demonstrating resilience amidst an...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

1 Healthcare Stock to Own for Decades and 2 We Avoid

November 13, 2025

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But speed bumps such as inventory destockings have persisted in the wake of COVID-19,...

Via StockStory

Topics Stocks

Tech Sector Tremors: Is the AI Bubble Deflating, and What's Next for the Market?

November 13, 2025

As of mid-November 2025, a palpable unease has settled over the technology sector, long the darling of investors and the primary engine of market growth. After a period of unprecedented outperformance,...

Via MarketMinute

Topics Artificial Intelligence Economy Stocks

Gilead’s Experimental One Pill Regimen Proved Non-Inferior To Multi-Pill Regimens In Treating HIV ↗

November 13, 2025

The company now plans to submit the data from the study to regulatory authorities.

Via Stocktwits

Gilead's One-Pill HIV Treatment Shows Promise In Late-Stage Trial ↗

November 13, 2025

Gilead's Phase 3 ARTISTRY-1 trial shows its single-tablet HIV regimen of bictegravir and lenacapavir matches the efficacy and safety of current therapy.

Via Benzinga

Explore the top gainers and losers within the S&P500 index in today's session. ↗

November 13, 2025

Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Thursday.

Via Chartmill

2 Supercharged Dividend Stocks to Buy Now ↗

November 13, 2025

Innovative drugmakers often make for solid dividend stocks. These two companies are great examples.

Via The Motley Fool

Topics ETFs Intellectual Property

This Gilead Sciences Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗

November 13, 2025

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

68 69 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.